IntrinsicIntrinsic
← All summaries

AYTU BIOPHARMA, INC

AYTU
Financials & Chart →

Business Summary

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases to improve the quality of life for patients. The company's strategy involves in-licensing, acquiring, developing, and commercializing novel prescription therapeutics to build a portfolio of revenue-generating products and leverage its commercial team's expertise. A significant recent development is the Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. in June 2025, to commercialize EXXUA (gepirone) extended-release tablets in the United States . EXXUA is described as a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of major depressive disorder (MDD) in adults . The company believes EXXUA has the potential to be a major growth catalyst and anticipates its launch in the fourth calendar quarter of 2025 .

The company's core business model is centered on generating revenue through the sale of prescription pharmaceutical products, primarily through third-party wholesalers and pharmacies. The business operates as a single operating and reporting segment, following the wind-down and divestiture of its Consumer Health business in the first quarter of fiscal 2025 . The revenue generation is transactional, based on product sales, with a focus on increasing market share through its internal commercial organization and leveraging its Aytu RxConnect patient access platform.

Aytu BioPharma's product and service lines from continuing operations consist of two primary portfolios: the ADHD Portfolio and the Pediatric Portfolio, with the upcoming addition of EXXUA. The ADHD Portfolio includes Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, both indicated for the treatment of ADHD . These products utilize the company's internally developed microparticle modified-release drug delivery technology platform, offering once-daily dosing and an orally disintegrating tablet formulation for easier administration . The Pediatric Portfolio primarily consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine, and Poly-Vi-Flor and Tri-Vi-Flor, which are complementary prescription fluoride-based multivitamin supplement product lines for infants and children with fluoride deficiency .

For the fiscal year ended June 30, 2025, Aytu BioPharma reported total net revenue of $66.382 million . The cost of goods sold was $20.551 million , resulting in a gross profit of $45.831 million and a gross profit percentage of 69% . Operating expenses totaled $53.658 million , leading to a loss from operations of $7.827 million . The net loss from continuing operations was $14.182 million , and the net loss for the period was $13.562 million . Diluted EPS from continuing operations was $(2.26) , while diluted EPS from discontinued operations was $0.10 , resulting in a total diluted EPS of $(2.16) . As of June 30, 2025, cash and cash equivalents were $30.952 million . Total debt, net of current portion, was $10.895 million .

Comparing fiscal year 2025 to fiscal year 2024, total net revenue increased by $1.199 million , or 2% . The Pediatric Portfolio saw a revenue increase of $1.489 million , reflecting a 20% increase from fiscal 2024 , attributed to a recently implemented return-to-growth plan. The ADHD Portfolio's net revenue was $57.576 million in fiscal 2025, a decrease of $0.208 million from $57.784 million in fiscal 2024. Gross profit decreased by $3.223 million , or 7% , with the gross profit percentage declining to 69% from 75% in the prior year, primarily due to increased cost of goods sold for ADHD Portfolio inventory burdened with fixed manufacturing costs. Selling and marketing expense decreased by $1.177 million , or 5% , while general and administrative expense decreased by $2.6 million , or 13% . Research and development expense decreased significantly by $1.443 million , or 52% . The company recognized an impairment expense of $8.263 million in fiscal 2025, compared to no impairment expense in fiscal 2024. Net cash used in operating activities increased to $1.937 million from $1.388 million .

During fiscal 2025, Aytu BioPharma completed the wind-down and divestiture of its Consumer Health business in the first quarter . The company successfully transitioned all manufacturing of its Adzenys and Cotempla products to a United States-based third-party contract manufacturer in the fourth quarter of fiscal 2024 to improve profitability . In June 2025, the company entered into an Exclusive Commercialization Agreement with Fabre-Kramer to commercialize EXXUA in the United States . The company also received a Paragraph IV Certification Notice Letter from Granules Pharmaceuticals, Inc. regarding a generic version of Adzenys and filed a patent infringement lawsuit on December 11, 2024, to trigger a 30-month stay on FDA approval . In June 2025, the company raised gross proceeds of $16.6 million from the issuance of common stock and prefunded warrants, with net proceeds of $14.8 million intended for working capital, general corporate purposes, and EXXUA commercialization. The Eclipse Agreement was amended in June 2025, increasing the Eclipse Term Loan principal to $13.0 million and the Eclipse Revolving Loan's potential maximum borrowing base to $14.5 million , with a temporary $1.5 million incremental advance .

Business Outlook

Aytu BioPharma anticipates launching EXXUA in the fourth calendar quarter of 2025, positioning it as a centerpiece of its commercial efforts . The company expects EXXUA to serve as a major growth catalyst, given its potential to compete in the over $22 billion United States prescription MDD market . The initial estimated useful life of the commercialization rights for EXXUA is expected to be through September 2030 .

The company plans to continue growing its commercial branded, revenue-generating products, specifically Adzenys, Cotempla, Karbinal, Poly-Vi-Flor, and Tri-Vi-Flor, by increasing product sales and improving patient access . This growth is expected to be driven by leveraging its internal commercial organization and advanced analytics platform to increase prescribing of its medicines . International commercial agreements have been established for Adzenys and Cotempla, with Medomie Pharma Ltd in Israel and the Palestinian Authority (July 2023) and Lupin Pharma Canada Ltd in Canada (September 2024), with local regulatory approvals and marketing authorizations expected over the next 24 months .

Operationally, Aytu BioPharma expects selling and marketing expense to increase during fiscal 2026 due to anticipated increases in prescription product sales related to the expected commercial launch of EXXUA . General and administrative expense is also expected to increase during fiscal 2026, primarily from increased costs associated with the initial launch and ongoing support of EXXUA . The company expects its research and development expenses to slightly decrease in the future as it continues to seek cost savings and focuses on commercial operations, with minimum R&D expenses related to required regulatory filings and intellectual property maintenance . The company does not anticipate any significant restructuring costs during fiscal 2026, as restructuring activities were completed during fiscal 2025 .

Planned capital allocation includes using the net proceeds of $14.8 million from the June 2025 public offering for working capital, general corporate purposes, and to enable the exclusive commercialization of EXXUA . The company has a shelf registration statement on Form S-3, declared effective on October 15, 2024, covering up to an aggregate of $100.0 million of various securities, with $100.0 million remaining available under the 2024 Shelf. Amortization of intangible assets is expected to increase in the future as the intangible asset related to EXXUA will increase over time when contingent consideration is capitalized as certain contingencies are met .

The company continues to experience inflationary pressures and economic uncertainty from global geopolitical factors and tariffs, and the industry is encountering supply chain disruptions related to raw materials, increased costs of materials, energy, logistics, and labor . These pressures and disruptions could be significant across the business throughout fiscal 2026 and into fiscal 2027 . The enactment of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, may adversely affect the company's business, financial condition, results of operations, and future plans, with certain provisions effective in calendar year 2025 and others through calendar year 2027 . The company is currently assessing the potential impact of the OBBBA .

Risk Factors

Aytu BioPharma faces several material risks, including the inherent uncertainty of achieving profitability, as the company has incurred losses since inception, with a net loss of $13.6 million for the year ended June 30, 2025, and an accumulated deficit of $333.5 million . The company is heavily dependent on the commercial success of its products, particularly the upcoming launch of EXXUA, and has not yet generated sufficient net revenue to achieve companywide profitability. There is a risk of increased competition, including the introduction of generic versions of its ADHD products, with Actavis having the right to market a generic version of Adzenys starting September 1, 2025 , and Teva having the right to market a generic version of Cotempla starting July 1, 2026 . Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact the company's ability to generate net revenue. The company relies on limited sources of supply and third parties for manufacturing, which could lead to production disruptions, increased costs, and delays. Furthermore, the company is subject to various federal and state laws pertaining to healthcare fraud and abuse, and its controlled substance products (Adzenys and Cotempla) are subject to stringent DEA regulations, including production quotas, which could limit commercialization. The company's ability to use its net operating loss carryforwards is limited by Section 382 of the IRC, with $324.7 million of federal net operating losses expected to expire unused by 2037 . Cybersecurity attacks, data leakages, or other security breaches pose a risk to the company's IT systems and data, potentially leading to reputational harm, litigation, or regulatory action.

Management Priorities

Management's message to shareholders emphasizes a focused strategy on advancing innovative medicines for complex CNS diseases to improve patient quality of life, with a clear commitment to enhancing lives through innovative treatments for MDD and ADHD and ensuring broad access. The company's strategic priorities are to increase net revenue and enhance financial performance through operational and manufacturing efficiencies and portfolio prioritization. Key strategic priorities include the successful launch of EXXUA in the fourth calendar quarter of 2025 as the centerpiece of commercialization efforts, continuing to grow commercial branded, revenue-generating products by increasing product sales and improving patient access, leveraging the Aytu RxConnect patient support platform to reduce access barriers, and improving gross margins for the ADHD product franchise through manufacturing transfer and additional margin improvement initiatives. Management expects selling and marketing expense to increase during fiscal 2026 related to anticipated increases in prescription product sales from the expected commercial launch of EXXUA, and general and administrative expense to increase during fiscal 2026 primarily from increased costs associated with the initial launch and ongoing support of EXXUA.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Company Overview
  2. [2] Item 1, Business — Company Overview
  3. [3] Item 1, Business — Company Overview
  4. [4] Item 1, Business — Company Overview
  5. [5] Item 1, Business — Company Overview
  6. [6] Item 1, Business — ADHD Product Portfolio Overview
  7. [7] Item 1, Business — Company Overview
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Gross Profit
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 8, Consolidated Balance Sheets
  20. [20] Item 8, Consolidated Balance Sheets
  21. [21] Item 7, MD&A — Net Revenue by Product Portfolio
  22. [22] Item 7, MD&A — Net Revenue by Product Portfolio
  23. [23] Item 7, MD&A — Net Revenue by Product Portfolio
  24. [24] Item 7, MD&A — Aytu Business
  25. [25] Item 7, MD&A — Net Revenue by Product Portfolio
  26. [26] Item 7, MD&A — Net Revenue by Product Portfolio
  27. [27] Item 7, MD&A — Net Revenue by Product Portfolio
  28. [28] Item 7, MD&A — Gross Profit
  29. [29] Item 7, MD&A — Gross Profit
  30. [30] Item 7, MD&A — Gross Profit
  31. [31] Item 7, MD&A — Gross Profit
  32. [32] Item 7, MD&A — Selling and Marketing
  33. [33] Item 7, MD&A — Selling and Marketing
  34. [34] Item 7, MD&A — General and Administrative
  35. [35] Item 7, MD&A — General and Administrative
  36. [36] Item 7, MD&A — Research and Development
  37. [37] Item 7, MD&A — Research and Development
  38. [38] Item 7, MD&A — Impairment Expense
  39. [39] Item 7, MD&A — Net Cash Used in Operating Activities
  40. [40] Item 7, MD&A — Net Cash Used in Operating Activities
  41. [41] Item 7, MD&A — Aytu Business
  42. [42] Item 7, MD&A — Aytu Business
  43. [43] Item 1, Business — Company Overview
  44. [44] Item 1, Business — Recent Business Development
  45. [45] Item 7, MD&A — Equity Financings
  46. [46] Item 7, MD&A — Equity Financings
  47. [47] Item 7, MD&A — Eclipse Agreement
  48. [48] Item 7, MD&A — Eclipse Agreement
  49. [49] Item 7, MD&A — Eclipse Agreement
  50. [50] Item 1, Business — Company Overview
  51. [51] Item 1, Business — Company Overview
  52. [52] Item 7, Note 7 — Intangible Assets
  53. [53] Item 1, Business — Strategy
  54. [54] Item 1, Business — Strategy
  55. [55] Item 1, Business — Commercial Business Overview
  56. [56] Item 7, MD&A — Selling and Marketing
  57. [57] Item 7, MD&A — General and Administrative
  58. [58] Item 7, MD&A — Research and Development
  59. [59] Item 7, MD&A — Restructuring Costs
  60. [60] Item 7, MD&A — Equity Financings
  61. [61] Item 7, MD&A — Equity Financings
  62. [62] Item 7, MD&A — Shelf Registrations
  63. [63] Item 7, MD&A — Shelf Registrations
  64. [64] Item 7, MD&A — Amortization of Intangible Assets
  65. [65] Item 7, MD&A — Business Environment
  66. [66] Item 7, MD&A — Business Environment
  67. [67] Item 7, MD&A — The One Big Beautiful Bill Act
  68. [68] Item 7, MD&A — The One Big Beautiful Bill Act
  69. [69] Item 1A, Risk Factors — Risks Related to Our Business and Financial Position
  70. [70] Item 1A, Risk Factors — Risks Related to Our Business and Financial Position
  71. [71] Item 1A, Risk Factors — Risks Related to Commercialization
  72. [72] Item 1A, Risk Factors — Risks Related to Commercialization
  73. [73] Item 7, Note 13 — Income Taxes
  74. [74] Item 7, Note 13 — Income Taxes

Analysis on 5/22/2026